Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04665206 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
A Phase 1 study of Solid Tumor, Adult and NSCLC, sponsored by Vivace Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 336
- Enrollment target
- 12
- Study locations
NCT04665206: Recruiting Phase 1 study of Solid Tumor, Adult and NSCLC, sponsored by Vivace Therapeutics.
NCT04665206 is a Phase 1 study of Solid Tumor, Adult and NSCLC that is actively recruiting participants, run by Vivace Therapeutics. The registered enrollment target is 336 participants, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (81% higher). The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04665206, a Phase 1 study of Solid Tumor, Adult and NSCLC, is actively recruiting participants, sponsored by Vivace Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 336 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Primary Outcome
Incidence of Adverse and Serious Adverse Events
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG VT3989
- DRUG Nivolumab & Ipilimumab
Study Locations (12)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Victoria
- Monash Health - Clayton
- Peter MacCullum Cancer Centre - Melbourne
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- University of Chicago Medical Center - Chicago
Minnesota
- M Health Fairview University of Minnesota Medical Center - Minneapolis
New York
- Memorial Sloan Kettering Cancer Center - New York
Virginia
- Virginia Cancer Specialists, PC - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2027-06-02 |
| Phase | Phase 1 |
What NCT04665206 shows while recruiting
NCT04665206 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (81% higher).
The record links to 3 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.
NCT04665206 lists 12 locations in 9 states (Massachusetts, Texas, Victoria).
Frequently Asked Questions
What is clinical trial NCT04665206 about?
NCT04665206 is a clinical study titled "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors". This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no...
What is the current status of trial NCT04665206?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 336 participants. The study started on 2021-03-24. Estimated completion is 2027-06-02.
What conditions does trial NCT04665206 study?
This clinical trial studies the following conditions: Solid Tumor, Adult, NSCLC, Mesothelioma.
What interventions are being tested in trial NCT04665206?
The interventions under investigation include: Osimertinib (DRUG), VT3989 (DRUG), Nivolumab & Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT04665206?
This trial is sponsored by Vivace Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04665206 being conducted?
This trial has 12 study locations across California, Illinois, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04665206's enrollment target sits among peer trials
336 13th of 72 higher than 60 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
- NCT05245500 · 336 participants · Phase 1
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI